The Changing Landscape of Breast Cancer Treatment

Area of Science:

• Oncology
• Translational Medicine
• Clinical Therapeutics

Background:

• Breast cancer management has shifted from aggressive surgery to personalized, multidisciplinary approaches.
• Tumor biology and patient-centered outcomes now guide treatment decisions.
• Recent advancements focus on less invasive surgical options and improved systemic therapies.

Purpose of the Study:

• To review the evolution of breast cancer management strategies.
• To highlight recent advances in systemic therapies and emerging treatment modalities.
• To discuss the current landscape and future challenges in breast cancer care.

Main Methods:

• Review of randomized trials and recent clinical advancements.
• Analysis of systemic therapies including targeted agents, antibody drug conjugates (ADCs), endocrine therapy, and immunotherapy.
• Exploration of emerging technologies like oral selective estrogen receptor degraders (SERDs), selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeric (PROTACs), and complete estrogen receptor antagonists (CERANs).

Main Results:

• Randomized trials support less invasive surgical options for select patients.
• Systemic therapies, including antibody drug conjugates (ADCs) like Trastuzumab emtansine (T-DM1) and Trastuzumab deruxtecan (T-Dxd), have improved survival and quality of life.
• Novel therapeutic agents are expanding treatment options for breast cancer.

Conclusions:

• Modern breast cancer management emphasizes precision medicine and multidisciplinary care.
• Less invasive surgical interventions are increasingly utilized in selected cases.
• Key challenges remain, including therapeutic resistance, treatment toxicity, cost, and equitable access to innovative therapies.